Therefore anticancer therapeutic strategies would be necessary to minimize the development of resistance to specific drugs and thus prolong remission. .
The idea behind a target-oriented therapeutic drug development for each cancer implicates the findings of well-understood molecular pathways in cancer in which it would require a multidisciplinary scientific approach. Relating to this idea, the discovery of HIV drugs involved a similar concept of a drug interacting with only a single target referred to as the 'magic bullet' and was ultimately accomplish from extensive laboratory research and scientific collaboration (Drews: 2006). However in the contemporary case of cancer, the concept of a 'magic bullet' would only be rational if the drug therapy was aimed at multiple targets of a distinct cancer, due to its complexity in forming drug resistance. Furthermore, computational analysis of cell division during tumor growth in response to a drug, show that although at least one cell will be resistant to the drug at the start of treatment, the use of two or more drugs significantly reduces the likelihood of a somatic mutant cell to generate because of its negative growth (Wodarz et al.: 2005). Hence the use of combing drugs and adjuvant therapy to target cell proliferation of distinct cancers will be crucial to the efficacy of drug-targeting therapy. .
By viewing the similar approaches used in situations of HIV-targeted treatments, indications in molecular pathways also observed in behaviors of distinct cancers may further aid in the development for a new drug. For instance, the development certain anti-HIV drugs involves the creation of synthetic peptides that imitate their analogous structure to inhibit the entry of the distinct HIV virus into target T cells, a cellular process known as viral entry inhibition (Drews: 2006).
